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The effectiveness of the trivalent seasonal influenza vaccine during
the 2014 season in South Africa was assessed using a test-negative
case–control study design including 472 cases and 362 controls.
Influenza A(H3N2) was the dominant strain circulating. The overall
vaccine effectiveness estimate, adjusted for age and underlying
conditions, was 431% (95% CI: 268–745). 2014 H3N2 viruses
from South Africa were mainly in sublineage 3C.3 with
accumulation of amino acid changes that differentiate them from
the vaccine strain in 3C.1.
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Introduction
In South Africa, annual influenza vaccination is recom-
mended for individuals at increased risk or healthy individ-
uals wishing to reduce their risk of contracting influenza.1 A
limited number of doses are available free of charge in the
public sector for high-risk groups, which include young
children, the elderly, pregnant or postpartum (within
2 weeks of delivery) women, and persons of any age with
underlying medical conditions (such as heart disease, lung
disease and HIV infection). In addition, anyone wishing to
protect themselves against influenza can purchase vaccine in
the private sector. The Southern Hemisphere trivalent
influenza vaccine (TIV) for 2014 contained an A/Califor-
nia/7/2009 (H1N1)-like virus; an A/Texas/50/2012 (H3N2)-
like virus; and a B/Massachusetts/2/2012-like virus, similar to
recommendations for the 2014/15 Northern Hemisphere
season. During the 2013/14 Northern Hemisphere influenza
season, vaccine effectiveness (VE) was shown to be 61% in
the USA,2 and 74% in Canada where influenza A(H1N1)
pdm09 predominated.3 New Zealand, in the Southern
Hemisphere, showed an interim 59% VE against hospitali-
sation and 74% effectiveness against medically attended acute
respiratory infection in the 2014 predominantly A(H1N1)
pdm09 season.4 However, influenza vaccine was not shown
to be effective in Spain in 2013–2014 season where A(H3N2)
strains predominated.5 Despite relatively low coverage
(35%) among patients attending general practitioners in
South Africa, TIV has been shown to be effective against
influenza-associated medically attended acute respiratory
illness using a test-negative case–control study design in years
when good vaccine strain match was reported (2010, 2011,
2013).6 We aimed to estimate TIV effectiveness against
laboratory-confirmed medically attended influenza illness for
the 2014 influenza season in South Africa and characterise
circulating strains.
Methods
The Viral Watch programme is an influenza sentinel
surveillance programme.7 In 2014, 101 outpatient practitio-
ners at 65 practices in eight of the nine provinces of South
Africa participated in the programme. Patients presenting
with influenza-like illness (ILI) to participating practitioners
and testing influenza virus positive were defined as cases,
whereas those who tested negative were controls. ILI was
defined as acute respiratory illness with a measured temper-
ature of ≥38°C or a history of fever, and cough, with onset
within the past 10 days. Throat and/or nasal swabs were
taken from a maximum of five patients per week as part of
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routine diagnostic investigations for which informed written
consent was not required. The choice of patients sampled was
left to the practitioner’s discretion.
Specimens were tested using multiplex reverse transcrip-
tion real-time polymerase chain reaction (rRT-PCR) assays
for influenza A and B. Influenza A-positive specimens were
further subtyped by rRT-PCR.8–10 The haemagglutinin (HA)
genes H3N2 strains from a convenience sample of partici-
pants from the beginning, mid- and end season (n = 34)
were amplified and sequenced, and phylogenetic analysis
using maximum-likelihood tree construction and pairwise
distances (p-distance) was performed for the HA1 region
(surface domain) using MEGA5.2.11 The number of N-linked
glycosylation sites was determined as described by Zhang
et al.12 Influenza virus isolation in Madin–Darby Canine
kidney cells was performed for influenza H3N2 virus-positive
samples with a crossing point threshold ≤30 (n = 30), and
antigenic reactivity of isolates (n = 26) was determined by
haemagglutination inhibition (HAI) assay using turkey red
blood cells as indicator and vaccine strain-specific antisera
produced in rabbits (HAI typing kit 2014; A/Texas/50/2012
Lot no. KAS414-1 VIDRL, WHO Collaborating Centre,
Melbourne, Australia).
Clinical, demographic and influenza vaccination data
were collected from each patient at the time of specimen
collection. Patients aged ≥6 months meeting the ILI case
definition with available influenza vaccine history were
included in the VE analysis. Vaccine history was self-
reported or from provider records, where available, and it
was not recorded whether children <9 years had received
two doses. Patients who had received the current season
influenza vaccine >14 days prior to the onset of illness were
considered vaccinated. Patients who had received influenza
vaccine ≤14 days prior to onset of symptoms were
excluded.
The start of the influenza season was defined as two
consecutive weekly influenza detection rates of ≥10%, and
the end as when the detection rate dropped below 10% for
two consecutive weeks, or <10 specimens per week were
received.7 The season was divided into three equal parts as
follows: early (weeks 21–26); mid (weeks 27–32); late (weeks
28–37). Finer time units were not used due to small sample
size. Only specimens collected during the season were
included in the VE analysis. Multivariate logistic regression
was used to adjust VE estimates by age, pre-existing
underlying medical conditions putting the patient at risk
of complications of influenza, and seasonality (first, mid or
last third of the season). Vaccine effectiveness was calculated
as 1-odds ratio for laboratory-confirmed influenza in
vaccinated and unvaccinated patients. All analyses were
conducted using STATA version 12.1 (Statacorp LP, College
Station, TX, USA.)
Results
The 2014 influenza season in South Africa started in week 21
(week ending 25 May) and ended in week 37 (week ending 14
September) during which time 857 individuals were enrolled
and tested and of whom 834 (973%) were eligible for the VE
analysis. Among individuals included, the overall influenza
detection rate was 566% (472/834). The season was dom-
inated initially by influenza A(H3N2) which accounted for
336/472 (712%) of the total influenza subtypes detected;
influenza B dominated in the last third of the season,
accounting for 44/71 (620%) of influenza detections
compared with 6/179 (34%) in the first third of the season.
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Figure 1. Test-negative controls and
laboratory-confirmed cases by week and virus
subtype: Viral Watch programme, South
Africa, 19 May – 14 September 2014.
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Influenza A(H1N1)pdm09 co-circulated throughout the
season in low numbers with a total of 54/472 (114%)
detections (Figure 1).
Nearly half (354, 422%) were patients aged 20–44 years,
and 437 (524%) patients were female. Mid-season spec-
imens accounted for 417% (348) of the total, although
this proportion was higher [222 (470%)] for cases. The
majority of specimens [743 (890%)] were collected within
3 days of symptom onset. Pre-existing underlying medical
conditions, such as chronic pulmonary and cardiac disease,
immunosuppression (including HIV), metabolic disorders,
pregnancy and morbid obesity defined as a body mass
index of ≥40, were reported in 149 (179%) patients
(Table 1).
Overall, the influenza vaccine coverage was 30% in cases
and 36% in controls. Coverage in patients with underlying
conditions was 65% in cases and 35% in controls and in
those aged ≥45 years was 59% in cases and 56% in
controls (Table 2). Of the 27 patients vaccinated, 14 were
positive for influenza A(H3N2), of whom 10 belonged to
groups at high risk for complications of influenza including
young children, the elderly, and persons with underlying
conditions.
The overall VE estimate, adjusted for age, underlying
conditions and seasonality, was 431% (95% CI: 268–745)
against any influenza virus type. The adjusted overall VE
estimate against influenza A(H3N2) was 184% (95% CI:
1715–484). We were not powered to obtain estimates
stratified by influenza strain, age group or the presence of
underlying illness.
The 2014 influenza A(H3N2) viruses from South Africa
(n = 34) were mainly in sublineage 3C.3 with accumulation
of amino acid changes that differentiate them from the
vaccine strain in 3C.1. (Figure 2). Vaccine breakthrough
infection strains (10/34) were characterised by S124N,
R142G and N145S mutations in epitope A and N128A and
S198P mutations in epitope B which is the same as for two-
thirds (16/24) of viruses from unvaccinated participants.
Amino acid p-distance between the 2014 vaccine strain was
increased in unvaccinated participants compared with
vaccinated in 2014 although not significantly (Mann–Whit-
ney two-tailed=0061) (Figure 3A). However, a significant
increase in nucleotide p-distance (Figure 3B) was observed
in strains from vaccinated participants (Mann–Whitney
two-tailed = 0007). Viruses from unvaccinated participants,
when compared to those from vaccinees, had an increased
number of potential N-linked glycosylation sites (Figure 3C)
similar to the vaccine strain, although not significant
(Mann–Whitney two-tailed = 0164). No difference was
observed in antigenic reactivity (Figure 3D) to vaccine
strain antisera between strains with <10 and those with
10 N-linked glycosylation sites (Mann–Whitney two-
tailed = 0624).
Discussion
Our point estimates for the Southern Hemisphere vaccine are
lower than (but not statistically different from) the interim
estimates reported from New Zealand where the 2014 season
was dominated by influenza A(H1N1)pdm09.4 This is the
second season, since the 2009 pandemic, that influenza A
(H3N2) was the dominant subtype in South Africa, and in
both seasons, we were unable to demonstrate significant VE,
with a 384% point estimate in 2012.13 It has been reported
elsewhere that VE against influenza A(H3N2) is often lower
than that against A(H1N1).10 Our VE results have occurred
in the context of an antigenic drift of the A(H3N2) viruses
which circulated in South Africa. Antibody binding sites for
Table 1. Characteristics of cases (influenza test positive) and controls
(influenza test negative) in the Viral Watch Programme, South Africa,
2014
Variable
Cases
N = 472
Controls
N = 362
Total
N = 834
Pn (%) n (%) n (%)
Age group
Median years 34 32 33 006
<20 years 131 (278) 107 (296) 238 (285)
20 – 44 years 189 (400) 165 (456) 354 (424)
≥45 years* 152 (322) 90 (248) 243 (291)
Sex
Male 230 (487) 165 (454) 395 (474) 041
Female 242 (513) 192 (530) 437 (524)
Unknown 2 (06) 2 (02)
Seasonality
Early (weeks 21–26) 179 (379) 153 (423) 332 (391) <001
Mid (weeks 27–32) 222 (470) 126 (348) 348 (417)
Late (weeks 33–37) 71 (150) 83 (2) 154 (185)
Region
Central Plateau** 265 (561) 175 (483) 440 (528) 003
North East
Subtropical***
60 (127) 66 (182) 126 (151)
Southern coastal belt† 147 (312) 121 (335) 268 (321)
Underlying condition††
None 379 (803) 304 (840) 683 (819) 037
Yes 92 (195) 57 (157) 149 (178)
Unknown 1 (02) 1 (03) 2 (03)
Interval between onset and sampling (days)
0–3 days 433 (917) 310 (856) 743 (891) <001
4–10 days 39 (83) 52 (144) 91 (109)
*We were unable to stratify by the age group ≥65 years due to small
numbers of patients in this age group.
**Free State, Gauteng, Northern Cape and North West Provinces.
***Mpumalanga and Limpopo Provinces.
†Eastern Cape and Western Cape Provinces.
††Chronic pulmonary and cardiac disease, chronic renal disease,
diabetes and similar metabolic disorders, immunosuppression, morbid
obesity (BMI ≥ 40), and pregnancy and post-parturition.
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neutralising antibodies induced by the 2014 vaccine strain
may have been masked or changed on haemaglutinin spikes
of viruses associated with vaccine breakthrough infections
which had lost an N-linked glycosylation site at position 124.
As expected, the lowest HAI titres were seen for viruses with
fewer glycosylation sites. The increase in nucleotide changes
in vaccine breakthrough infection strains that are synony-
mous do not change the HA1 protein and antigenicity but
may negatively affect viral RNA signalling or packaging
which could decrease viral replication and survival of these
variants.14–16 These findings highlight the importance of the
continuous monitoring of genetic changes in the haemaglu-
tinin domain during seasonal epidemics.
The Northern Hemisphere influenza vaccine composition
for the 2014–2015 season was the same as the vaccine
composition used during the Southern Hemisphere 2014
influenza season.13 During the 2014/15 season, the United
Kingdom experienced circulation of A(H3N2) and mid-
season estimates showed an adjusted VE of 34% against
primary care consultation and 23% against laboratory-
confirmed influenza.17 Influenza A(H3N2) circulating in
Europe was antigenically and/or genetically different from
the vaccine strain.18 The 2014/15 season in North America
has also been dominated by influenza A(H3N2). In the
United States, early VE estimates indicated that the
influenza vaccine provided limited protection.19 In Canada,
interim-unmatched VE estimates adjusted for age and
medical comorbidities were determined to be 168%
overall, and 220% for laboratory-confirmed influenza A
(H3N2).20 Viruses clustered with phylogenetic clade 3C.2a
considered genetically and antigenically different from the
vaccine strain. Interim-adjusted VE against A(H3N2) was
8%.21 During spring 2014, drifted influenza A(H3N2)
viruses, subgroup 3C.3a, were detected in Finland. Another
subgroup, 3C.2a emerged in the 2014/15 season and has
predominated. Antibody response data suggested reduced
protection against vaccine strain.22 Both these subgroups
were detected in South Africa during the 2014 season
Figure 2.
There are several limitations to our study which was not
specifically designed to assess VE and, given the available
data, we were not powered to statistically assess significance
of VE estimates lower than 80%. In addition, the low vaccine
coverage affected the ability to statistically estimate signifi-
cance of VE among smaller subgroups such as the elderly
(>65 years of age). Influenza vaccine status and underlying
conditions were self-reported by some patients to the
practitioner which could have led to misclassification and
residual confounding. In addition, a higher proportion of
controls had a longer period between onset and collection
which can introduce misclassification bias through false
negatives. Our study population mainly included individuals
accessing private health care through general practitioners
and may not be representative of the public sector where
vaccine coverage is lower.6 The gold standard for determin-
ing antigenic profiles of influenza viruses is the HAI assay
using ferret antisera and number of isolates obtained for HAI
assays was small.
Conclusions
Based on our data, the 2014 TIV had a <50% point estimate
for effectiveness against outpatient ILI in South Africa.
Previous estimates from South Africa using the same
methodology have found TIV to be effective in this
population.
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Table 2. Vaccine receipt and vaccine effectiveness (VE) estimates by the presence of underlying medical conditions (UMC), age group and timing
within season, Viral Watch Programme, South Africa, 2014
Vaccine coverage
Percentage crude VE (95%CI)
Cases Controls Total
n/N (%) n/N (%) n/N (%)
Total 14/472 (30) 13/362 (36) 27/834 (32) 179 (768, 619)
UMC 6/92 (65) 2/57 (35) 8/149 (54) 919 (8848, 626)
No UMC 8/379 (21) 11/307 (36) 19/683 (28) 426 (446, 772)
<20 years 1/131 (08) 2/107 (19) 3/238 (13) 596 (3513, 964)
20–44 years 4/189 (21) 6/165 (36) 10/354 (28) 427 (1067, 841)
≥45 years 9/152 (59) 5/90 (56) 14/242 (58) 7 (2298, 653)
Early season (weeks 21–26) 1/126 (08) 1/130 (08) 2/256 (08) 32 (1568, 362)
Mid-season (weeks 27–32) 12/223 (54) 7/103 (68) 19/326 (58) 220 (1043, 702)
Late season (weeks 33–37) 1/123 (08) 5/129 (39) 6/252 (24) 797 (765, 766)
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Figure 2. Maximum-likelihood tree of the A(H3N2) HA1 region (850 bp) including strains from the South African 2014 influenza season. The 2014 VW
strains are indicated by circles (black = vaccine breakthrough strains). The 2014 Southern Hemisphere (SH) vaccine strain A/Texas/50/2012 is indicated by a
black square. The emerging sub-subgroups 3C.2a and 3C.3a with low reactivity to the current vaccine are indicated. Haemagglutination inhibition titres
are indicated next to strains (** low reactors).
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